• Highly successful career pathway with 30 years of international health care experience, including 12 years at J&J and most recently as Vice President of Sales and Marketing in a med-tech startup.
• Unique experience portfolio that started as head of the Department of Interventional Cardiology in a University Hospital followed by extensive international experience in medical device multinationals and startups.
• Strong strategic and conceptual thinker and highly effective communicator and influencer.

• Business Development and Commercialization of specialty cardiac and vascular devices across EMEA.

• Credible clinical and commercial leadership, able to influence market entry all the way from clinical through regulatory and reimbursement towards commercialization.

• Ability to create business opportunities though a unique balance of technical and commercial insight.

• Build and lead multifunctional international teams mastering the complexity associated with the high-end medical device business.

• Ability to forge collaborative, lasting relationships with key thought leaders.

• Demonstrated ability to adapt and thrive in a wide range of cultures and environment

(*) as Executive Consultant

January 2013 - Today: CALIBER THERAPEUTICS, NY US

• Vice President of Operations (*)

2012 - 2013:  SURPASS MEDICAL INC. FL US

• International Vice President of Sales and Marketing (*)
• Launched Surpass’ technology in the complex area of interventional neuroradiology by recruiting staff, building commercial platform and develop a strong supporting KOL network. The company got acquired by Stryker in November 2012 for $135M.

2009 – 2011:  STENTYS SAS. Paris, France

• Vice President of Sales and Marketing.
  • Turned around the company’s strategic focus thus laying the base for targeted commercialization of its pioneering technology
  • Defined and implemented both Europe-wide and country-specific business development strategies through solid KOL-, Health Economics- (e.g. NUB Status 1 in Germany), Clinical- and Geographical Expansion initiatives
  • Hit or exceeded all company milestones: 2010 and 2011YTD revenues; timely recruitment of top class European commercial team consisting of 11 senior business leaders and marketers; timely enrollment in clinical trials; consistent communication and strong KOL endorsement.
  • In one year, managed to establish a strong commercial footprint in 15 target countries through a unique balance of seasoned sales executives and a selection of highly motivated distributors.  

2006 – 2009: CORDIS JOHNSON & JOHNSON, Brussels Belgium

• Director of Marketing Endovascular EMEA
  • Member of the EMEA board
  • 3 major launches of disruptive technologies for the treatment of obstructive vascular low limb disease supported by a multidisciplinary team
  • Director of CCVI (Cordis Cardiac and Vascular Institute) with world-class training facilities in Hamburg Germany
  • Pre-market assessment for fully percutaneous AAA system
  • Lead of a major cross-franchise market development program targeting type 2 diabetes

2004 – 2006: CORDIS JOHNSON & JOHNSON, Brussels Belgium

• Director of Business development Endovascular and Neurovascular
  • Member of the EMEA board
  • 15% year to year growth in developing markets with 5% CAGR
  • Lead ‘ACTION’ market development program focusing on timely referral of patients with endovascular or neurovascular disease.
  • Lead country specific reimbursement projects through tight cooperation with HTA’s and payers.
  • Global Leadership Award for extraordinary performance

2001 – 2004: CORDIS JOHNSON & JOHNSON, Brussels Belgium

• Director Neurovascular EMEA
  • Installed pan-European team of clinical specialists and sales/marketing managers
  • Grew intracranial coil- and intracranial stent businesses from FIM to €30+Mln  in 2 years
  • Lead Cordis Neurovascular towards successful integration into the Codman franchise
  • Master green belt in Process Excellence

1998 – 2001: CORDIS JOHNSON & JOHNSON, Brussels Belgium

• Marketing Manager Cardiology Stents EMEA
  • Drove commercialization of Bx Velocity from FIM to market leader with €250+Mln in revenues 2 years after J&J acquired Cordis.
  • Bx Velocity served as the platform for the benchmark Cypher DES, launched in 2002

1991 – 1998: BOC Ohmeda, Bilthoven Netherlands

• Product Manager Benelux Viggo Spectramed
• Sales Manager Spectramed Belgium
  • Successfully converted from distributor business to direct business with 4 sales reps doubling the company’s profit in a period of 2 years.
• Sales Representative Spectramed Belgium

1989 – 1991: Baxter SA, Brussels Belgium

• Sales representative for Baxter’s new LIS division, pioneering in Interventional Cardiology

1981 – 1989: University Hospital Antwerp Belgium

• Head of the department of Interventional Cardiology
  • Lead 14 staff
  • From zero to 1500 PCI’s